Detection of resectable pancreatic cancer with SOMAmer proteomic technology.

162 Background: To improve the current dismal 5-year survival rates for pancreatic adenocarcinoma (PC) it is essential to develop strategies focused on detection in high-risk populations. This study employed a unique SOMAmer proteomics platform to identify a biomarker panel that discriminates between pancreatic cancer and control patients. A secondary goal was to compare the panel with CA 19-9. Methods: Plasma samples (total < 20 ul) were analyzed for 825-proteins using a SOMAmer proteomics platform on training set of 100 cases and 69 controls from a single institution. The control group contained individuals with GI symptoms, including acute and chronic pancreatitis, and normal controls. An independent blinded validation set from another center consisted of 43 PC patients and 47 controls. About two thirds (96/143) of the study cases were in resectable stages I-IIb. Biomarkers were identified by Random Forest backwards selection, using a false-discovery-rate corrected value of p<0.001. CA19-9 levels were ...